4.2 Review

New Imaging Modalities in Bone

Journal

CURRENT RHEUMATOLOGY REPORTS
Volume 13, Issue 3, Pages 241-250

Publisher

SPRINGER
DOI: 10.1007/s11926-011-0174-x

Keywords

Osteoporosis; Bone quality; Radiography; Computed tomography; Magnetic resonance imaging; Image analysis

Categories

Funding

  1. Merck Co.
  2. Novartis
  3. Servier
  4. Bristol-Myers Squibb
  5. GlaxoSmithKline
  6. Roche
  7. Eli Lilly and Company
  8. Genentech
  9. Amgen
  10. Ono Pharmaceutical Co.

Ask authors/readers for more resources

The digital era has witnessed an exponential growth in bone imaging as new modalities and analytic techniques improve the potential for noninvasive study of bone anatomy, physiology, and pathophysiology. Bone imaging very much lends itself to input across medical and engineering disciplines. It is in part a reflection of this multidisciplinary input that developments in the field of bone imaging over the past 30 years have in some respects outshone those in many other fields of medicine. These developments have resulted in much deeper knowledge of bone macrostructure and microstructure in osteoporosis and a much better understanding of the subtle changes that occur with age, concurrent disease, and treatment. This new knowledge is already being translated into improved day-to day clinical care with better recognition, treatment, and monitoring of the osteoporotic process. As the more you know, the more you know you don't know certainly holds true with osteoporosis and bone disease, there is little doubt that further advances in bone imaging and analytical techniques will continue to hold center stage in osteoporosis and related research.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available